COVID infection has been linked to higher risk of autoimmune disorders, including rheumatoid arthritis and type 1 diabetes. Scientists used advanced data analysis and machine learning to identify viral proteins that are more likely to trigger autoimmunity.
Nebraska undergrads uncover ancient secrets of human immunity
New research from the University of Chicago shows how a specially trained population of immune cells keeps the peace by preventing other immune cells from attacking their own.
Scientists at Washington University School of Medicine in St. Louis and the Perelman School of Medicine at the University of Pennsylvania have identified a key component to launching immune activity – and overactivity. The researchers identified a protein in cells that spurs the release of infection-fighting molecules. The protein, whose role in the immune system had not previously been suspected, provides a potential target for therapies that could prevent overreactive immune responses that are at the root of several debilitating illnesses.
Protein kinase research presents an opportunity to explore molecular targets in the body to treat diseases like cancer and autoimmune disorders. These enzymes have the potential to bind to cellular sites and inhibit dysfunctional behavior, such as the overproduction of cancerous cells and tumor formation.
Two new studies led by researchers at Hospital for Special Surgery (HSS) have uncovered key biological mechanisms driving systemic sclerosis (SSc), or scleroderma – a rare and often devastating autoimmune disease that causes fibrosis (tissue hardening) and inflammation. The research, published in the March issue of the Journal of Experimental Medicine, helps explain why the disease disproportionately affects women and reveals potential treatment targets, some of which are already in development.
A new study of hundreds of patient records has added to evidence that it’s likely best to use as little corticosteroid medicine as possible when treating people who have lupus, a common heart complication of the autoimmune disorder.
"If we can target these molecules in human patients, they might be able to develop long-lasting tolerance to allergens."
A sponge-like implant in mice helped guide a treatment that slowed or stopped a degenerative condition similar to multiple sclerosis in humans. It also gave University of Michigan researchers a first look at how primary progressive multiple sclerosis, the fastest-progressing version of the disease, attacks the central nervous system early on.
Pesquisadores da Mayo Clinic identificaram uma terapia direcionada que pode trazer alĂvio para as pessoas que vivem com lĂquen plano, uma condição inflamatĂłria crĂ´nica da pele, cabelo, unhas, boca e genitais. Eles descreveram suas descobertas em um estudo publicado no Journal of Clinical Investigation, relatando seu primeiro ensaio clĂnico em humanos, fase 2.
Investigadores de Mayo Clinic han identificado una terapia dirigida que puede brindar alivio a las personas que viven con liquen plano, una condiciĂłn inflamatoria crĂłnica de la piel, cabello, uñas, boca y genitales. Ellos escribieron sus hallazgos en un estudio publicado en el Journal of Clinical Investigation, informando su primer ensayo clĂnico en humanos, fase 2.
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition of the skin, hair, nails, mouth and genitals. They described their findings in a study published in the Journal of Clinical Investigation that described their first-in-human, phase 2 clinical trial.
Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes to treatment.Cutaneous lupus erythematosus is a common manifestation of systemic lupus erythematosus.The condition is characterized by rashes on various parts of the body including the face and scalp, hair loss and scarring of the skin.
The University of Chicago Medicine has launched a Phase 2 clinical trial to study how CAR T-cell therapy could be used to treat three autoimmune diseases.
Houston Methodist researchers have identified a key protein as a potential therapeutic target for stopping the body’s immune system from mistakenly attacking itself, offering new hope for treating autoimmune diseases and allergies.
Patients with cutaneous lupus erythematosus (CLE), an autoimmune disease that causes skin inflammation, have a higher risk for atherosclerotic cardiovascular disease (ASCVD), or hardening of the arteries, UT Southwestern Medical Center researchers found. Their study, published in JAMA Dermatology, suggests CLE patients should be screened early for heart disease.
20221027104337.jpg&width=400&height=400)
Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Carla Moran MB BCh, BAO, PhD awarded the ATA's Van Meter Award for outstanding contributions to thyroid research.
Recovery from an autoimmune inflammation of the brain may take three years or more, according to a study published in the November 20, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to Rutgers Health researchers.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right